Cargando…

Implication of genetic variants in primary microRNA processing sites in the risk of multiple sclerosis

BACKGROUND: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system with a well-established genetic contribution to susceptibility. Over 200 genetic regions have been linked to the inherited risk of developing MS, but the disease-causing variants and their functional...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hecker, Michael, Fitzner, Brit, Putscher, Elena, Schwartz, Margit, Winkelmann, Alexander, Meister, Stefanie, Dudesek, Ales, Koczan, Dirk, Lorenz, Peter, Boxberger, Nina, Zettl, Uwe Klaus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9111935/ https://www.ncbi.nlm.nih.gov/pubmed/35561450 http://dx.doi.org/10.1016/j.ebiom.2022.104052

Ejemplares similares

Transcriptome alterations in peripheral blood B cells of patients with multiple sclerosis receiving immune reconstitution therapy
por: Hecker, Michael, et al.
Publicado: (2023)

Genetic risk variants for multiple sclerosis are linked to differences in alternative pre-mRNA splicing
por: Putscher, Elena, et al.
Publicado: (2022)

A genetic variant associated with multiple sclerosis inversely affects the expression of CD58 and microRNA-548ac from the same gene
por: Hecker, Michael, et al.
Publicado: (2019)

Principles and Practical Considerations for the Analysis of Disease-Associated Alternative Splicing Events Using the Gateway Cloning-Based Minigene Vectors pDESTsplice and pSpliceExpress
por: Putscher, Elena, et al.
Publicado: (2021)

Microarray data of transcriptome shifts in blood cell subsets during S1P receptor modulator therapy
por: Koczan, Dirk, et al.
Publicado: (2018)

Fingolimod alters the transcriptome profile of circulating CD4+ cells in multiple sclerosis
por: Friess, Jörg, et al.
Publicado: (2017)

Leukocyte Telomere Length in Patients with Multiple Sclerosis and Its Association with Clinical Phenotypes
por: Hecker, Michael, et al.
Publicado: (2021)

Systematic Review of Studies on Telomere Length in Patients with Multiple Sclerosis
por: Bühring, Jan, et al.
Publicado: (2021)

Genetic, Environmental and Lifestyle Determinants of Accelerated Telomere Attrition as Contributors to Risk and Severity of Multiple Sclerosis
por: Hecker, Michael, et al.
Publicado: (2021)

The Cerebrospinal Fluid in Multiple Sclerosis
por: Deisenhammer, Florian, et al.
Publicado: (2019)

Reduced Fragmentation of IGFBP-2 and IGFBP-3 as a Potential Mechanism for Decreased Ratio of IGF-II to IGFBPs in Cerebrospinal Fluid in Response to Repeated Intrathecal Administration of Triamcinolone Acetonide in Patients With Multiple Sclerosis
por: Hoeflich, Andreas, et al.
Publicado: (2021)

MicroRNA Expression Changes during Interferon-Beta Treatment in the Peripheral Blood of Multiple Sclerosis Patients
por: Hecker, Michael, et al.
Publicado: (2013)

Vaccination in Multiple Sclerosis: Friend or Foe?
por: Zrzavy, Tobias, et al.
Publicado: (2019)

Systemic Effects by Intrathecal Administration of Triamcinolone Acetonide in Patients With Multiple Sclerosis
por: Hoeflich, Andreas, et al.
Publicado: (2020)

Abnormal Pre-mRNA Splicing in Exonic Fabry Disease-Causing GLA Mutations
por: Alfen, Franziska, et al.
Publicado: (2022)

Glatiramer acetate treatment effects on gene expression in monocytes of multiple sclerosis patients
por: Thamilarasan, Madhan, et al.
Publicado: (2013)

Therapeutic plasma exchange in steroid-refractory multiple sclerosis relapses. A retrospective two-center study
por: Blechinger, Stephan, et al.
Publicado: (2021)

Reassessment of Blood Gene Expression Markers for the Prognosis of Relapsing-Remitting Multiple Sclerosis
por: Hecker, Michael, et al.
Publicado: (2011)

Analysis of microRNA and Gene Expression Profiles in Multiple Sclerosis: Integrating Interaction Data to Uncover Regulatory Mechanisms
por: Freiesleben, Sherry, et al.
Publicado: (2016)

Elevated type I interferon-like activity in a subset of multiple sclerosis patients: molecular basis and clinical relevance
por: Hundeshagen, Alexander, et al.
Publicado: (2012)

Polypharmacy in patients with multiple sclerosis: a gender-specific analysis
por: Frahm, Niklas, et al.
Publicado: (2019)

Rituximab versus mitoxantrone: comparing effectiveness and safety in advanced relapsing multiple sclerosis
por: Zrzavy, Tobias, et al.
Publicado: (2021)

Polypharmacy in outpatients with relapsing-remitting multiple sclerosis: A single-center study
por: Frahm, Niklas, et al.
Publicado: (2019)

Multi-drug use among patients with multiple sclerosis: A cross-sectional study of associations to clinicodemographic factors
por: Frahm, Niklas, et al.
Publicado: (2019)

Vaccination and multiple sclerosis in the era of the COVID-19 pandemic
por: Monschein, Tobias, et al.
Publicado: (2021)

Side effects following vaccination in multiple sclerosis: a prospective, multi-centre cohort study
por: Winkelmann, Alexander, et al.
Publicado: (2023)

The risk of polypharmacy, comorbidities and drug–drug interactions in women of childbearing age with multiple sclerosis
por: Frahm, Niklas, et al.
Publicado: (2020)

Multiple Sclerosis: Modulation of Toll-Like Receptor (TLR) Expression by Interferon-β Includes Upregulation of TLR7 in Plasmacytoid Dendritic Cells
por: Derkow, Katja, et al.
Publicado: (2013)

Tick-borne encephalitis vaccination in multiple sclerosis: A prospective, multicenter study
por: Winkelmann, Alexander, et al.
Publicado: (2019)

Vaccination Coverage against Tetanus, Diphtheria, Pertussis and Poliomyelitis and Validity of Self-Reported Vaccination Status in Patients with Multiple Sclerosis
por: Langhorst, Silvan Elias, et al.
Publicado: (2022)

Depression and Anxiety in Association with Polypharmacy in Patients with Multiple Sclerosis
por: Baldt, Julia, et al.
Publicado: (2023)

Chronic Progressive Multiple Sclerosis – Pathogenesis of Neurodegeneration and Therapeutic Strategies
por: Fitzner, Dirk, et al.
Publicado: (2010)

Prevalence and Severity of Potential Drug–Drug Interactions in Patients with Multiple Sclerosis with and without Polypharmacy
por: Bachmann, Paula, et al.
Publicado: (2022)

Associated factors of potential drug-drug interactions and drug–food interactions in patients with multiple sclerosis
por: Debus, Jane Louisa, et al.
Publicado: (2022)

The pathophysiology of motor fatigue and fatigability in multiple sclerosis
por: Patejdl, Robert, et al.
Publicado: (2022)

Comparative evaluation of patients’ and physicians’ satisfaction with interferon beta-1b therapy
por: Zettl, Uwe Klaus, et al.
Publicado: (2016)

Correlation of Nabiximols Dose to Steady-State Concentrations of Cannabinoids in Urine Samples from Patients with Multiple Sclerosis
por: Birke, Rüdiger, et al.
Publicado: (2022)

Therapy of women with multiple sclerosis: an analysis of the use of drugs that may have adverse effects on the unborn child in the event of (unplanned) pregnancy
por: Haker, Marie-Celine, et al.
Publicado: (2023)

Screening for severe drug-drug interactions in patients with multiple sclerosis: A comparison of three drug interaction databases
por: Hecker, Michael, et al.
Publicado: (2022)

Effects of normobaric hypoxic endurance training on fatigue in patients with multiple sclerosis: a randomized prospective pilot study
por: Zrzavy, Tobias, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_08au7o9nre6tnt1c67mpke0gmo